1. Academic Validation
  2. Macrophage and neutrophil death programs differentially confer resistance to tuberculosis

Macrophage and neutrophil death programs differentially confer resistance to tuberculosis

  • Immunity. 2021 Aug 10;54(8):1758-1771.e7. doi: 10.1016/j.immuni.2021.06.009.
Michael Dominic Stutz 1 Cody Charles Allison 1 Samar Ojaimi 1 Simon Peter Preston 1 Marcel Doerflinger 1 Philip Arandjelovic 1 Lachlan Whitehead 1 Stefanie M Bader 1 Daniel Batey 1 Marie-Liesse Asselin-Labat 1 Marco J Herold 1 Andreas Strasser 1 Nicholas P West 2 Marc Pellegrini 3
Affiliations

Affiliations

  • 1 The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • 2 School of Chemistry and Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia.
  • 3 The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia. Electronic address: pellegrini@wehi.edu.au.
Abstract

Apoptosis can potently defend against intracellular pathogens by directly killing microbes and eliminating their replicative niche. However, the reported ability of Mycobacterium tuberculosis to restrict apoptotic pathways in macrophages in vitro has led to Apoptosis being dismissed as a host-protective process in tuberculosis despite a lack of in vivo evidence. Here we define crucial in vivo functions of the death receptor-mediated and BCL-2-regulated Apoptosis pathways in mediating protection against tuberculosis by eliminating distinct populations of infected macrophages and neutrophils and priming T cell responses. We further show that apoptotic pathways can be targeted therapeutically with clinical-stage compounds that antagonize inhibitor of Apoptosis (IAP) proteins to promote clearance of M. tuberculosis in mice. These findings reveal that any inhibition of Apoptosis by M. tuberculosis is incomplete in vivo, advancing our understanding of host-protective responses to tuberculosis (TB) and revealing host pathways that may be targetable for treatment of disease.

Keywords

IAP antagonist; Mycobacterium tuberculosis; apoptosis; caspase; cell death; macrophages; pyroptosis.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15518
    99.91%, IAP Inhibitor
    IAP